Abiopharma

🔍 BUTITTA CYNTHIA M (Director)

Company: UroGen Pharma Ltd. (URGN)

Report Date: 2025-08-26

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Stock Option (right ot buy) at $19.5 per share (Derivative)
  Date: 2025-08-26 | Code: A | Expires: 2035-08-26 | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 8,000 shares of Restricted Stock Unit (Derivative)
  Date: 2025-08-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
• F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
• F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.